Oral Capsule Microbiota Transplantation for Severe Refractory C. difficile Infection with Metabolic Complications
A 49-year-old patient suffering from persistent Clostridioides difficile (C. difficile) infection achieved clinical remission after receiving an investigational oral microbiota product, according to a case report published in Cureus.
The patient, who faced life-threatening complications due to underlying distal renal tubular acidosis (RTA), saw her daily bowel movements drop from 13 to five within one week of the transplant.
Key Clinical Takeaways:
- Oral microbiota capsules served as a successful rescue therapy for a patient who failed to respond to multiple standard antibiotic regimens.
- The patient’s recovery was complicated by severe electrolyte imbalances and hypoalbuminemia, highlighting the risks of combining fulminant colitis with pre-existing metabolic disorders.
The clinical course began when the patient, already managed for distal RTA since September 2024, presented with severe diarrhea. Although initial tests for C. difficile were negative, a readmission one week later confirmed a positive toxin and PCR assay. By this time, the patient’s condition had escalated to fulminant colitis, characterized by 40 bowel movements per day and severe hypovolemia, as documented in Cureus.
The patient’s underlying RTA—a condition preventing the distal nephron from excreting hydrogen ions—created a volatile environment. The profound gastrointestinal losses exacerbated her systemic metabolic acidosis and hypokalemia. Hospital staff managed the patient in the intensive care unit for six days to stabilize her biochemistry, including a nadir serum albumin level of 11 g/L.
Medical teams initially utilized aggressive standard-of-care protocols, including oral vancomycin and intravenous metronidazole. When these failed to resolve the infection, the patient was transitioned to an extended course of pulsed oral fidaxomicin. Despite this escalation, imaging on readmission day 11 revealed worsening pancolitis and diffuse subcutaneous edema, indicating that the infection remained uncontrolled.
With surgical intervention considered but ultimately deferred, clinicians accessed an investigational multi-donor full-spectrum microbiota product (EBX-102, EnteroBiotix Ltd) on a compassionate use basis.
Following an antibiotic washout period, the patient received the oral capsules. The intervention was well-tolerated, and by day seven post-transplantation, the patient’s stool frequency had decreased significantly. Biochemical markers also showed steady improvement, with serum albumin rising to 32 g/L by the seventh day following the procedure.
At a two-week outpatient follow-up, the patient showed no clinical evidence of recurrence. This case suggests that for patients with complex metabolic comorbidities, traditional antibiotic strategies may be insufficient to break the cycle of dysbiosis. While fecal microbiota transplantation (FMT) is well-established for recurrent CDI, this report shows it can serve as an acute inpatient rescue therapy.
While this case demonstrates the efficacy of oral microbiota products in a specific, high-risk scenario, researchers continue to explore the broader applications of gut microbiome modulation. Ongoing investigations are examining the potential of FMT in treating conditions such as inflammatory bowel disease, irritable bowel syndrome, and metabolic syndromes, including insulin resistance. Early-stage research also focuses on the gut-brain axis as a potential target for Parkinson’s disease and multiple sclerosis.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.